EXEL Jun 2024 22.000 call
| Previous Close | 0.8800 |
| Open | 0.9000 |
| Bid | 0.7000 |
| Ask | 0.8500 |
| Strike | 22.00 |
| Expire Date | 2024-06-21 |
| Day's Range | 0.6500 - 0.9000 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 3.1k |
ZacksExelixis (EXEL) Settles Cabometyx Patent Litigation With Cipla
Exelixis (EXEL) resolves two patent litigations and grants Cipla a license to market generic versions of Cabometyx in the United States beginning January 2031.
Business WireExelixis Announces Settlement of CABOMETYX® (cabozantinib) Patent Litigation with Cipla Limited and Cipla USA
ALAMEDA, Calif., May 20, 2024--Exelixis, Inc. (Nasdaq: EXEL) today announced that it has entered into a Settlement and License Agreement (Agreement) with Cipla Ltd. and Cipla USA, Inc. (collectively Cipla). This settlement resolves two patent litigations brought by Exelixis in response to Cipla’s Abbreviated New Drug Application (ANDA) seeking approval to market generic versions of CABOMETYX® (cabozantinib) tablets prior to the expiration of the applicable patents. The first case (Civil Action N
Business WireExelixis to Webcast Fireside Chats as Part of Investor Conferences in May
ALAMEDA, Calif., May 07, 2024--Exelixis, Inc. (Nasdaq: EXEL) today announced that members of the company’s management team will participate in fireside chats at the following investor conferences in May:
